The use of partial liquid ventilation (PLV) with perfluorocarbons in neonates, children and adults with acute lung injury/acute respiratory distress syndrome is associates with improvement in gas exchange and pulmonary function. Cardiopulmonary interaction with the long-term effects of toxicity requires further study. However, extrapolations from data obtained in animals suggests that no long-term adverse effects exist. The information available indicates that continuous monitoring is required and that ventilador should be adjusted during administration of this drug to reduce hypoxemia, hemodynamic complications and pneumothorax. Further clinical studies are required to explore the efficacy of PLV in acute lung injury/acute respiratory distress syndrome and in particular to determine the short-and long-term toxic effects. To answer these and other questions additional research is undoubtedly required.
|Translated title of the contribution||Liquid ventilation|
|Number of pages||8|
|State||Published - Jan 1 2001|
- Liquid ventilation
ASJC Scopus subject areas
- Critical Care and Intensive Care Medicine